Floatz logo

DARATUMUMAB

Aplastic Anemia

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkinsmonoclonal_antibodyEarly Phase 1Active
C
39/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
24/ 100
Competitive Position
95/ 100

Competitive context

15 Active assets in the Aplastic Anemia cohort.

Asset / SponsorPhaseRating
Fludarabine
Thomas Jefferson University
Phase 2BBB
Cyclophosphamide
Thomas Jefferson University
Phase 3BBB
TACROLIMUS
Thomas Jefferson University
Phase 2BB
FILGRASTIM
Thomas Jefferson University
Phase 2BB
Anti-Thymoglobulin, Rabbit
M.D. Anderson Cancer Center
Phase 3BB

View all 36 →

Same molecule, other indications

DARATUMUMAB is also rated in:

plasma cell myelomaDormant
BB
Indicative ·
67 / 100
View asset →
smoldering plasma cell myelomaDormant
BB
Indicative ·
65 / 100
View asset →
diffuse large B-cell lymphomaDormant
BB
Indicative ·
65 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →